Table 2.
Period | Pre-PCV 1998-2003 |
Early 2005-2009 |
Routine 2011-2015 |
% change* | p value** |
---|---|---|---|---|---|
All cause pneumonia | |||||
POPULATION | 20.6 | 21.4 | 28.4 | +32.7% | *** |
< 5 year | 67.5 | 57.4 | 34.3 | −40.2% | *** |
5-14 | 8.0 | 9.8 | 7.0 | −28.6% | 0.031 |
15-24 | 2.8 | 2.7 | 2.2 | −18.5% | 0.103 |
24-44 | 5.0 | 4.9 | 4.6 | −6.1% | 0.246 |
45-64 | 12.6 | 12.2 | 13.9 | +13.9% | 0.018 |
> 64 | 63.0 | 62.8 | 90.9 | +44.7% | *** |
Pneumococcal pneumonia | |||||
POPULATION | 6.3 | 5.7 | 2.4 | −57.9% | *** |
< 5 | 25.2 | 12.6 | 2.1 | −83.3% | *** |
5-14 | 2.6 | 2.3 | 0.5 | −78.3% | *** |
15-24 | 0.7 | 0.8 | 0.2 | −75.0% | *** |
24-44 | 1.4 | 1.3 | 0.5 | −61.5% | *** |
45-64 | 3.4 | 3.2 | 1.5 | −53.1% | *** |
> 64 | 19.5 | 17.6 | 7.4 | −58.0% | *** |
Invasive diseases | |||||
POPULATION | 6.5 | 6.0 | 2.7 | −55.0% | *** |
< 5 | 25.8 | 13.3 | 2.3 | −82.7% | *** |
5-14 | 2.7 | 2.3 | 0.6 | −73.9% | *** |
15-24 | 0.7 | 0.8 | 0.3 | −62.5% | *** |
24-44 | 1.5 | 1.5 | 0.6 | −60.0% | *** |
45-64 | 3.5 | 3.4 | 1.7 | −50.0% | *** |
> 64 | 19.9 | 18.1 | 8.0 | −55.8% | *** |
*% change comparing private market use and routine immunization.
**p-value according to one-way ANOVA
***p < 0.0001